MassDevice.com +5 | The top 5 medtech stories for August 11, 2016
Say hello to MassDevice +5, a bite-sized view of the top five medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 5 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry. Get this in your inbox everyday by subscribing to our newsletters. 5. GI Dynamics looks to next year for 2nd bite at FDA apple for EndoBarrier GI Dynamics is hoping to make another run at FDA approval for its flagship EndoBarrier treatment for obesity and diabetes after its 1st try failed last year. In a presentation accompanying the release of its 2nd-quarter numbers, the Lexington, Mass.-based medical device company said it’s busy repairing its relationship with the FDA and plans to finalize a bid for another investigational device exemption during the 1st half of 2017; GI Dynamics said it hopes to begin enrollment in the IDE trial by the end of June 2017. Read more 4. Spectranetics releases final 1-year results for Stellarex drug-coated balloon Spectranetics today released the final 1-year results from the Illumenate EU RCT study comparing treatment with its Stellarex drug-coated balloon to percutaneous transluminal angioplasty, touting a 24% higher rate of primary patency with the DCB. One-year results from the 328-patient trial were presented at the Amputation Prevention Symposium in Chicago this week. Read more 3. Avinger pric...
Source: Mass Device - Category: Medical Equipment Authors: MassDevice Tags: News Well Plus 5 Source Type: news
More News: Angioplasty | Baloon Angioplasty | Diabetes | Eating Disorders & Weight Management | Endocrinology | Genetics | Insulin | Medical Devices | Obesity | Peripheral Angioplasty | Peripheral Vascular Disease (PVD) | Skin | Skin Graft | Study